The 13th International AIDS Society Conference on HIV Science (IAS 2025) is taking place in Kigali, Rwanda, and virtually, ...

And although the evidence is clearer for viral STIs like HPV and mpox, the bacterial STIs that doxycycline can prevent may take a more aggressive course in people with HIV, especially if they have low ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

A CRISPR-based gene-editing therapy called EBT-101 was safe and well tolerated but did not prevent viral rebound in three participants who stopped antiretroviral treatment in an early study, according ...

A once-weekly oral regimen can keep HIV suppressed as well as daily pills, according to study results presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2024). In a ...

The San Francisco Department of Public Health (SF DPH) was ahead of the game, issuing doxyPEP recommendations a year earlier and getting a head start on compiling real-world data. San Francisco’s ...

BHIVA recommends that people aged 40 and over should be offered a statin irrespective of lipid levels or estimated cardiovascular risk. People with HIV aged 40 and over with an estimated 10-year risk ...

Budigalimab, a monoclonal antibody that blocks the PD-1 receptor on immune cells, was associated with delayed HIV rebound or sustained low viral load in a majority of people who interrupted ...

In some cases, HIV can bypass the barrier that encases the brain and cerebrospinal fluid which can contribute to brain inflammation and neurocognitive symptoms. However, diagnosing this viral ‘escape’ ...

Lenacapavir, the first HIV capsid inhibitor, has a long half-life in the body, allowing it to be administered by subcutaneous injection just once every six months. It also comes in an oral formulation ...